Ultrafiltrazione peritoneale e sindrome cardiorenale: gestione del sovraccarico di fluidi e ruolo del sodio

Abstract

Peritoneal ultrafiltration and cardiorenal syndrome: management of fluid congestion and role of sodium

Congestion represents a crucial clinical component of both heart failure and cardiorenal syndrome and it has been postulated to modulate heart and kidney cross-link. Diuretic therapy is a corner stone in the treatment patients with heart failure, and renal replacement therapies are mainly used for patients with refractory heart failure who have not reached the worst stages of renal disfunction. Peritoneal dialysis is a home-based therapeutic modality providing both solute clearance and ultrafiltration, together with relief from congestion in decompensated heart failure patients. The following review will focus on sodium removal in refractory decompensated heart failure patients undergoing peritoneal dialysis.

Keywords

Heart failure Cardiorenal syndrome Peritoneal dialysis Sodium removal

Get full access to this article

View all access options for this article.

References

Lloyd-Jones

Larson

Leip

et al . Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106:3068-3072.

Gheorghiade

Zannad

Sopko

et al . International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112:3958-3968.

Kazory

Elkayam

Cardiorenal interactions in acute decompensated heart failure: contemporary concepts facing emerging controversies. J Card Fail 2014; 20:1004-1011.

Ronco

Bellasi

Di Lullo

Cardiorenal Syndrome: An Overview. Adv Chronic Kidney Dis 2018; 25(5):382-390.

Metra

Cotter

Gheorghiade

Dei Cas

Voors

AA.

The role of the kidney in heart failure. Eur Heart J 2012; 33:2135-2142.

Mullens

Abrahams

Francis

et al . Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53:589-596.

Kazory

Cardiorenal syndrome: ultrafiltration therapy for failure – trials and tribulations. Clin J Am Soc Nephrol 2013; 8(10):1816-1828.

Kazory

Ultrafiltration Therapy for Heart Failure: Balancing Benefits against Possible Risks. Clin J Am Soc Nephrol 2016; 11(8):1463-1471.

Kazory

Peritoneal dialysis for chronic cardiorenal syndrome: lessons learned from ultrafiltration trials. World J Cardiol 2015; 7(7):392-396.

10.

Muciño-Bermejo

Ribeiro

et al . Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med 2015; 5(2):145–156.

11.

Kazory

Fluid overload as a major target in management of cardiorenal syndrome: implications for the practice of peritoneal dialysis. World J Nephrol 2017; 6(4):168-175.

12.

Volpe

Tritto

DeLuca

et al . Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure. Circulation 1993; 88(4 Pt 1):1620-1627.

13.

Rodríguez-Carmona

Fontán

MP.

Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 2002; 22(6):705-713.

14.

Wang

Lin

Yen

Lin

Yao-Lung

Sung

FC.

Icodextrin reduces the risk of congestive heart failure in peritoneal dialysis patients. Pharmacoepidemiol Drug Saf 2018; 27(4):447-452.

15.

Fourtounas

Dousdampanis

Hardalias

Vlachojannis

JG.

Sodium removal and peritoneal dialysis modalities: no differences with optimal prescription of icodextrin. Artif Organs 2013; 37(7):E107-13.

16.

Borrelli

La Milia

De Nicola

et al . Study group Peritoneal Dialysis of Italian Society of Nephrology. Sodium removal by peritoneal dialysis: a systematic review and meta-analysis. J Nephrol 2018. doi: 10.1007/s40620-018-0507-1

17.

Vychytil

Hörl

WH.

The role of tidal peritoneal dialysis in modern practice: A European perspective. Kidney Int Suppl 2006; 70(103):S96-103.

18.

Agar

Sloand

JA.

Single Daily Icodextrin Exchange as Initial and Solitary Therapy. Perit Dial Int 2018; 38(2):119-124.

19.

Fischbach

Zaloszyc

Schaefer

Schmitt

CP.

Optimizing peritoneal dialysis prescription for volume control: the importance of varying dwell time and dwell volume. Pediatr Nephrol 2014; 29(8):1321–1327.

20.

Fischbach

Haraldsson

Dynamic changes of the total pore area available for peritoneal exchange in children. J Am Soc Nephrol 2001; 12(7):1524–1529.

21.

Ivarsen

Povlsen

Jensen

JD.

Increasing fill volume reduces cardiac performance in peritoneal dialysis. Nephrol Dial Transplant 2007; 22(10):2999-3004.

22.

Rutkowski

Tam

van der Sande

et al . Low Sodium Balance Study Group. Low-Sodium Versus Standard-Sodium Peritoneal Dialysis Solution in Hypertensive Patients: A Randomized Controlled Trial. Am J Kidney Dis 2016; 67(5):753761.

23.

Freida

Issad

Dratwa

et al . A combined crystalloid and colloid pd solution as a glucose-sparing strategy for volume control in high-transport apd patients: a prospective multicenter study. Perit Dial Int 2009; 29(4):433–442.

24.

Dousdampanis

Trigka

Chu

et al . Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center’s experience and review of the literature. Int Urol Nephrol 2011; 43(1):203-209.

25.

Ballout

Garcia-Lopez

Struyven

Maréchal

Goffin

Double-dose icodextrin to increase ultrafiltration in PD patients with inadequate ultrafiltration. Perit Dial Int 2011; 31(1):91-94.

26.

Fischbach

Issad

Dubois

Taamma

The beneficial influence on the effectiveness of automated peritoneal dialysis of varying the dwell time (short/long) and fill volume (small/large): a randomized controlled trial. Perit Dial Int 2011; 31(4):450-458.

27.

Öberg

Rippe

Is Adapted APD Theoretically More Efficient than Conventional APD?

Perit Dial Int 2017; 37(2):212-217.